163 related articles for article (PubMed ID: 2988591)
1. Pre-dosing plasma concentrations and beta-adrenoceptor blocking effects during repeated once daily dosing with 160 mg sustained-release propranolol (Inderal LA) and 16/260 oxprenolol Oros to healthy volunteers.
Moppert J; Degen PH; Racine-Poon A
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):197S-201S. PubMed ID: 2988591
[TBL] [Abstract][Full Text] [Related]
2. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers.
Woods KL; Jack DB; Kendall MJ; Halsey A; O'Donnell ML; Warrington SJ; John VA
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):177S-184S. PubMed ID: 4005120
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.
Leahey WJ; Neill JD; Varma MP; Shanks RG
Eur J Clin Pharmacol; 1980 Jun; 17(6):419-24. PubMed ID: 7398733
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation.
Kerr MJ; Harron DW; Kinney C; Shanks RG
Br J Clin Pharmacol; 1981 Dec; 12(6):869-71. PubMed ID: 6122463
[TBL] [Abstract][Full Text] [Related]
5. Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers.
Bennett PN; Bennett J; Bradbrook I; Francis J; John VA; Rogers H; Turner P; Warrington SJ
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):171S-175S. PubMed ID: 4005119
[TBL] [Abstract][Full Text] [Related]
6. Observations on some properties of a long-acting preparation of propranolol.
Shanks RG; Neill JD; Leahey WJ; Varma MP
Clin Sci (Lond); 1979 Dec; 57 Suppl 5():409s-411s. PubMed ID: 540460
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations.
Perucca E; Grimaldi R; Gatti G; Caravaggi M; Crema F; Lecchini S; Frigo GM
Br J Clin Pharmacol; 1984 Jul; 18(1):37-43. PubMed ID: 6743489
[TBL] [Abstract][Full Text] [Related]
8. Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.
Müller FB; Allsopp LF; Cooper GL; Bolli P; Frei P; Glaus L; Ritz R; Bühler FR
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):207S-212S. PubMed ID: 4005124
[TBL] [Abstract][Full Text] [Related]
9. Twenty-four hour effects of oxprenolol Oros and atenolol on heart rate, blood pressure, exercise tolerance and perceived exertion.
van Baak MA; Verstappen FT; Oosterhuis B
Eur J Clin Pharmacol; 1986; 30(4):399-406. PubMed ID: 3743615
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical effects of propranolol (Inderal) with once daily slow-release oxprenolol (Slow Trasicor) in angina pectoris.
Majid PA; de Feijter PJ; Wardeh R; van der Wall EE; Roos JP
J Int Med Res; 1979; 7(3):194-200. PubMed ID: 378729
[TBL] [Abstract][Full Text] [Related]
11. Concentration-effect relationships for oxprenolol in patients with essential hypertension.
McInnes GT; Brodie MJ
Br J Clin Pharmacol; 1988 May; 25(5):539-45. PubMed ID: 3408634
[TBL] [Abstract][Full Text] [Related]
12. Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis.
Racine-Poon A; Moppert J
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):143S-149S. PubMed ID: 4005116
[TBL] [Abstract][Full Text] [Related]
13. Slow release oxprenolol in angina pectoris: study comparing oxprenolol, once daily, with propranolol, four times daily.
Olowoyeye JO; Thadani U; Parker JO
Am J Cardiol; 1981 May; 47(5):1123-7. PubMed ID: 7223659
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.
McInnes GT; Brodie MJ
Eur J Clin Pharmacol; 1988; 34(6):605-11. PubMed ID: 3169112
[TBL] [Abstract][Full Text] [Related]
15. CNS-related performance and haemodynamics of metoprolol-Oros and propranolol after single and 3 days dosing in healthy volunteers.
van Steveninck AL; Pieters MS; Schoemaker HC; Breimer DD; Cohen AF
Br J Clin Pharmacol; 1993 Feb; 35(2):114-20. PubMed ID: 8443028
[TBL] [Abstract][Full Text] [Related]
16. Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade.
McDevitt DG; Brown HC; Carruthers SG; Shanks RG
Clin Pharmacol Ther; 1977 May; 21(5):556-66. PubMed ID: 15753
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers.
Aellig WH
Eur J Clin Pharmacol; 1978 Nov; 14(3):167-9. PubMed ID: 729611
[TBL] [Abstract][Full Text] [Related]
18. Reproducibility of oxprenolol plasma concentrations in young female volunteers following oral administration of an oxprenolol Oros dosage form.
Jack DB; Kendall MJ; Laugher SJ; Smith SR
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):185S-190S. PubMed ID: 4005121
[TBL] [Abstract][Full Text] [Related]
19. Influence of food intake on plasma oxprenolol concentrations following oral administration of conventional and Oros preparations.
John VA; Smith SE
Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):191S-195S. PubMed ID: 4005122
[TBL] [Abstract][Full Text] [Related]
20. A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.
West MJ; Kendall MJ; Mitchard M; Faragher EB
Br J Clin Pharmacol; 1976 Jun; 3(3):439-43. PubMed ID: 788749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
